Financial Perspectives Inc Purchases 233 Shares of Bristol-Myers Squibb (NYSE:BMY)

Financial Perspectives Inc grew its position in Bristol-Myers Squibb (NYSE:BMY) by 28.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,066 shares of the biopharmaceutical company’s stock after buying an additional 233 shares during the period. Financial Perspectives Inc’s holdings in Bristol-Myers Squibb were worth $55,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of BMY. OFI Invest Asset Management acquired a new stake in Bristol-Myers Squibb during the 3rd quarter valued at $25,000. Milestone Investment Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at $27,000. Blue Bell Private Wealth Management LLC increased its stake in shares of Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 200 shares during the period. Legacy Financial Group LLC acquired a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at $39,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $40,000. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on BMY. Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Finally, William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Stock Down 0.3 %

Shares of Bristol-Myers Squibb stock traded down $0.14 during trading on Tuesday, reaching $49.00. The stock had a trading volume of 9,147,169 shares, compared to its average volume of 15,525,874. The company has a market capitalization of $99.31 billion, a price-to-earnings ratio of 12.76, a P/E/G ratio of 1.48 and a beta of 0.39. The stock has a fifty day moving average price of $51.22 and a two-hundred day moving average price of $51.38. Bristol-Myers Squibb has a 52 week low of $47.58 and a 52 week high of $70.93. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.82 earnings per share. Sell-side analysts predict that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.90%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.